DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis

Published:2006-01-01 Issue:12 Volume:47 Page:2558-2566
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Mey Ulrich J. M.¹,Olivieri Attilio²,Orlopp Katjana S.¹,Rabe Christian¹,Strehl John W.¹,Gorschlueter Marcus¹,Hensel Manfred³,Flieger Dimitri⁴,Glasmacher Axel G.¹,Schmidt-Wolf Ingo G. H.¹

Affiliation:

1. Department of Internal Medicine I, University of Bonn, Germany

2. Department of Hematology, Ancona University, Italy

3. Department of Internal Medicine V, University of Heidelberg, Germany

4. Department of Internal Medicine II, Klinikum Aschaffenburg, Germany

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428190600926572

Reference47 articles.

1. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: Results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study

2. Diffuse Aggressive Lymphoma

3. Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

4. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

5. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma;British Journal of Haematology;2022-04

2. Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report;Frontiers in Oncology;2022-01-18

3. Rituximab biosimilars for lymphoma in Europe;Expert Opinion on Biological Therapy;2019-09-30

4. Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2018-10

5. Efficacy of rituximab combined with CHOP for treating patients with diffuse large B-cell lymphoma;Medicine;2017-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3